Biodel Inc. (BIOD)
()
 
 

Overview

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at www.biodel.com.


Contact Information

100 Saw Mill Road
Danbury, CT 06810

tel: 203-796-5000
fax: 203-796-5001
http://www.biodel.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $368.4M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.